{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:43:57Z","timestamp":1791179037570,"version":"4.1.0"},"reference-count":20,"publisher":"American Diabetes Association","issue":"1","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":3978,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,1,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>To test the hypothesis that exenatide twice daily reduces the relative incidence of cardiovascular disease (CVD) events among patients with type 2 diabetes compared with other glucose-lowering agent(s).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>A retrospective database analysis was performed of the LifeLink database of medical and pharmaceutical insurance claims for June 2005 through March 2009. Patients with no history in the preceding 9 months of myocardial infarction, ischemic stroke, or coronary revascularization procedure were assigned to the exenatide-initiated or non\u2013exenatide-initiated cohorts based on the first new prescription filled and reassigned if exenatide was prescribed or discontinued. Incident CVD events (myocardial infarction, ischemic stroke, or coronary revascularization procedure) were identified by ICD-9-CM diagnosis codes. Patient outcomes were adjusted for differences in clinical and demographic characteristics and compared using propensity score\u2013weighted discrete time survival analysis with time-varying exposure to exenatide.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>A total of 39,275 patients with type 2 diabetes were treated with exenatide twice daily, and 381,218 patients were treated with other glucose-lowering therapies. Patients who initiated exenatide were more likely to have prior ischemic heart disease, obesity, hyperlipidemia, hypertension, and\/or other comorbidities at baseline. Exenatide-treated patients were less likely to have a CVD event than non\u2013exenatide-treated patients (hazard ratio 0.81; 95% CI 0.68\u20130.95; P = 0.01) and lower rates of CVD-related hospitalization (0.88; 0.79\u20130.98; P = 0.02) and all-cause hospitalization (0.94; 0.91\u20130.97; P &amp;lt; 0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Exenatide twice-daily treatment was associated with a lower risk of CVD events and hospitalizations than treatment with other glucose-lowering therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc10-1393","type":"journal-article","created":{"date-parts":[[2010,10,8]],"date-time":"2010-10-08T00:38:59Z","timestamp":1286498339000},"page":"90-95","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":208,"title":["Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies"],"prefix":"10.2337","volume":"34","author":[{"given":"Jennie H.","family":"Best","sequence":"first","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron J.","family":"Hoogwerf","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Herman","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, Michigan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise M.","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, IMS Health, Watertown, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Smith","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, IMS Health, Watertown, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Made","family":"Wenten","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, San Diego, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Hussein","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, IMS Health, Falls Church, Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2010,10,7]]},"reference":[{"key":"2022031218270791600_B1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2337\/diacare.22.2.233","article-title":"The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 124 years","volume":"22","author":"Coutinho","year":"1999","journal-title":"Diabetes Care"},{"key":"2022031218270791600_B2","doi-asserted-by":"crossref","first-page":"6S","DOI":"10.1016\/j.amjmed.2003.09.009","article-title":"Hyperglycemia as a cardiovascular risk factor","volume":"115","author":"Haffner","year":"2003","journal-title":"Am J Med"},{"key":"2022031218270791600_B3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/oxfordjournals.aje.a114266","article-title":"Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women","volume":"123","author":"Pan","year":"1986","journal-title":"Am J Epidemiol"},{"key":"2022031218270791600_B4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"2022031218270791600_B5","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031218270791600_B6","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031218270791600_B7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031218270791600_B8","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031218270791600_B9","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031218270791600_B10","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"2022031218270791600_B11","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"2022031218270791600_B12","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"2022031218270791600_B13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-151-6-200909150-00137","article-title":"Systematic review: glucose control and cardiovascular disease in type 2 diabetes","volume":"151","author":"Kelly","year":"2009","journal-title":"Ann Intern Med"},{"key":"2022031218270791600_B14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2022031218270791600_B15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/0895-4356(93)90103-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives","volume":"46","author":"Romano","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"2022031218270791600_B16","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780195152968.001.0001","volume-title":"Applied Longitudinal Data Analysis","author":"Singer","year":"2003"},{"key":"2022031218270791600_B17","doi-asserted-by":"crossref","first-page":"b4909","DOI":"10.1136\/bmj.b4909","article-title":"The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study","volume":"340","author":"Bonds","year":"2010","journal-title":"BMJ"},{"key":"2022031218270791600_B18","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/01.mlr.0000160417.39497.a9","article-title":"Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors","volume":"43","author":"Birman-Deych","year":"2005","journal-title":"Med Care"},{"key":"2022031218270791600_B19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","article-title":"Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records","volume":"148","author":"Kiyota","year":"2004","journal-title":"Am Heart J"},{"key":"2022031218270791600_B20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0895-4356(97)00040-1","article-title":"Validation of pharmacy records in drug exposure assessment","volume":"50","author":"Lau","year":"1997","journal-title":"J Clin Epidemiol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/34\/1\/90\/608016\/zdc00111000090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/34\/1\/90\/608016\/zdc00111000090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T19:28:18Z","timestamp":1647113298000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/34\/1\/90\/27991\/Risk-of-Cardiovascular-Disease-Events-in-Patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,7]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,10,7]]},"published-print":{"date-parts":[[2011,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc10-1393","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,7]]}}}